Vaporizer vs. Joint: Effects, Exposure, and Practical Differences

A joint combusts cannabis; a dry-herb vaporizer heats flower to produce an aerosol. Controlled comparisons show less exhaled carbon monoxide with the vaporizer studied, whilst THC uptake continues. In infrequent users, the acute effect of the same nominal THC quantity may be more pronounced after vaporization. A blanket percentage for health benefit, bioavailability, or material saving cannot be derived from this. Abrams et al. (2007) Spindle et al. (2018)

What exactly is being compared?

“Joint” can refer to a pure cannabis cigarette or a tobacco–cannabis mixture. For scientific comparison, this is far from a trivial distinction. Tobacco adds an additional exposure; switching from a tobacco joint to a tobacco-free vaporizer therefore changes more than just the heating method. Anyone applying study findings must keep these differences in mind. Muheriwa-Matemba et al. (2024) Ghasemiesfe et al. (2018)

The controlled trial by Abrams used standardised cannabis cigarettes. Spindle, by contrast, had participants smoke from a small pipe. The second study is an important comparison of smoked and vaporized cannabis, but it is not a direct trial with hand-rolled tobacco joints. Both studies used a specific Volcano system. The findings cannot be transferred unchanged to all portable devices, ball vapes, or cartridges. Abrams et al. (2007) Spindle et al. (2018)

Comparison by key criteria

Criterion	Joint or smoked cannabis	Dry-herb vaporizer
Process	Combustion of the material	Regulated or manual heating to produce an aerosol
Combustion markers	Higher exhaled CO in direct trials	Lower exhaled CO in direct trials; not universally zero emissions Abrams et al. (2007)
THC effect	Dependent on product and use	Not automatically weaker; in one small acute-use study, effects were frequently stronger at the same nominal dose Spindle et al. (2018)
Long-term comparison	Respiratory symptoms examined mainly in observational studies	Fewer direct data on long-term clinical endpoints Muheriwa-Matemba et al. (2024) Ghasemiesfe et al. (2018)
Effort	Consumables and disposal	Purchase, cleaning, power, and replacement parts where applicable
Cost assessment	Dependent on actual consumption	No study-supported general savings figure

Why can the same quantity of flower produce different effects?

The mass loaded into a device is only the start of the chain of effects. The potency of the starting material, transfer into smoke or aerosol, deposition within the device, and individual uptake together determine the exposure. The amount actually inhaled is therefore not identical to the quantity of THC loaded. Device recovery and bioavailability must be considered separately. Lanz et al. (2016) Hazekamp et al. (2006)

In the Spindle study, the mean peak THC concentration in whole blood following a nominal THC dose of 25 mg was 14.4 ng/ml with vaporizing and 10.2 ng/ml with smoking. 17 adults who had not used cannabis in the preceding month were studied. Individual values varied considerably. This is an example of why less respiratory irritation does not necessarily mean less acute effect. It is not a conversion table for one’s own use. Spindle et al. (2018)

The apparently divergent findings of Abrams, who observed similar THC exposure, are not a reason to disregard a study. The populations, starting material, and methods of administration differed. It is precisely this range that is scientifically meaningful: there is no single universal relationship applicable to every consumption situation. Abrams et al. (2007) Spindle et al. (2018)

What changes for the airways?

The lower CO exposure observed in direct comparisons and laboratory findings on combustion products point to a different exposure profile. Whether and to what extent this translates into fewer long-term illnesses is not answered by these experiments. The claim of ‘no tar and no CO’ is just as problematic without a precise measurement definition as a general figure for all harmful substances. Abrams et al. (2007) Gieringer et al. (2004) Moir et al. (2008)

A small, non-randomised switching study found improvements in symptoms and one lung function parameter in a selected subgroup after one month. A cross-sectional survey found fewer symptoms among primary dry-herb vaporizer users. Both studies have substantial limitations and do not provide a reliable prediction of the percentage by which a given individual would reduce their disease risk. Van et al. (2010) Earleywine et al. (2007)

Where smoking and vaping are combined, exposure to smoke persists. The PATH analysis of young adults found increased odds of newly occurring respiratory symptoms associated with this dual use. Given the observational design and the insufficiently granular product data captured, no precise causal effect of combined use may be calculated from this. Sun et al. (2026)

How can the actual costs be compared?

An honest cost comparison requires your own observed inputs. These include the purchase price, replacement parts, energy, consumables, and the amount of material actually used over the same period. A high extraction value from a laboratory study is no guarantee of lower personal expenditure: frequency of use and consumption may change following a switch in device.

A transparent calculation reads: Total costs over the period = purchase price and replacement parts + ongoing material costs + energy and consumables. The formula is a financial consideration, not a study finding. If costs are spread over months, the assumed service life must remain visible. No blanket saving should be entered for the material — only a documented quantity.

A break-even calculation only makes sense if the ongoing costs are actually lower. With the same or greater frequency of use, a device may appear cheaper to run without paying for itself overall. Current offers are listed in the price comparison; no medical assessment follows from the price.

What practical differences remain?

With a dry-herb vaporizer, the chamber, screens, and vapour path become part of the regular maintenance burden. Swappable dosing capsules can make preparation more convenient, but they do not define an exact absorbed THC dose. A portable device requires a suitable power source; a desktop device requires a suitable location. These characteristics are technical selection criteria, not health-related quality grades.

Taste, draw resistance, and the perceived temperature of the aerosol are personal sensations. They can be systematically documented in your own device comparison. However, they are not analytical measurements: a pleasant taste proves neither the absence of harmful substances nor low potency. For scientific conclusions, sensory and chemical measurements must remain separate. Lanz et al. (2016)

Which decision does the evidence support?

Anyone wishing to understand the difference should consider combustion-related exposure, THC effects, and everyday practicality separately. The dry-herb route examined reduces certain combustion markers, but does not eliminate THC exposure. General claims about a ‘healthiest’ brand or a fixed saving percentage go beyond what the literature supports. Muheriwa-Matemba et al. (2024) Abrams et al. (2007) Spindle et al. (2018)

The health article puts remaining risks into context. Smoking vs. vaporizing covers cough, lung function, and the limitations of more recent cohort studies. Dry herb vs. concentrates prevents the common confusion between dry-herb vaporizers and THC cartridges.

Studies in detail: methods, results and limitations

The following boxes make the key sources and their limits of transferability transparent. A device study or pharmacokinetics study does not automatically constitute evidence of long-term health safety. For technical articles, the studies are often relevant only to the explicitly stated distinction between health claims and yield claims.

Abrams DI et al. (2007)

Study

Randomised controlled pilot study, repeated measures

Sample

18 healthy inpatient cannabis users

Comparison and measurement

Comparison of a standardised smoked cannabis cigarette versus the Volcano vaporizer; plasma THC, exhaled CO, physiological and neuropsychological effects.

Randomisation and blinding

Yes. Cannabis potency (1.7%, 3.4%, 6.8% THC) and delivery system were randomly assigned across six study days.

Result

THC exposure was similar between smoking and vaporizing; exhaled CO was markedly lower after vaporization; no serious adverse events.

Strengths

Direct controlled head-to-head comparison; objective biomarkers; randomised.

Limitations and potential bias

Very small sample; pilot in nature; older and lower THC potencies compared with today’s products; no long-term endpoints.

Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL. 2007. Vaporization as a smokeless cannabis delivery system: a pilot study. Clinical pharmacology and therapeutics. DOI: 10.1038/sj.clpt.6100200 · PMID 17429350

Spindle TR et al. (2018)

Study

Controlled crossover study within the same participants; dose blinded, inhalation route apparent.

Sample

17 healthy adults; 9 male, 8 female; mean age 27.3 years; no cannabis use in the preceding month.

Comparison and measurement

Six sessions with 1-week washout; 0, 10, and 25 mg THC, each smoked or vaporized; subjective effects, cognition, psychomotor performance, vital signs, and blood THC.

Randomisation and blinding

Dose order within inhalation blocks randomised, order of inhalation routes counterbalanced. Dose blinding employed; no double-dummy procedure to blind inhalation route.

Result

Vaporization generally produced stronger acute effects and higher peak blood THC at equivalent THC doses; at 25 mg, Cmax approximately 14.4 ng/ml vaporized vs 10.2 ng/ml smoked.

Strengths

Placebo condition, within-person comparisons, multiple doses, and objective whole-blood measurements.

Limitations and potential bias

n=17; infrequent users only; acute laboratory study; no conclusions on long-term pulmonary or overall morbidity.

Spindle TR, Cone EJ, Schlienz NJ, Mitchell JM, Bigelow GE, Flegel R, Hayes E, Vandrey R. 2018. Acute Effects of Smoked and Vaporized Cannabis in Healthy Adults Who Infrequently Use Cannabis: A Crossover Trial. JAMA network open. DOI: 10.1001/jamanetworkopen.2018.4841 · PMID 30646391 · PMC6324384

Muheriwa-Matemba SR et al. (2024)

Study

Systematic review

Sample

42 included publications: 6 case reports, 21 reviews, 15 empirical studies; among the empirical studies are 2 RCTs, 5 retrospective analyses, 3 longitudinal studies, and 3 cross-sectional studies.

Comparison and measurement

Web of Science, ProQuest, PsycINFO, Scopus, Embase, and Medline; peer-reviewed publications 2009–2023; PRISMA; only studies with documented route of administration.

Randomisation and blinding

Not at the review level; only a small proportion of the primary studies were randomised.

Result

Smoking was most consistently associated with respiratory symptoms and conditions; edibles showed little direct respiratory effect; tachycardia was reported across several routes of administration.

Strengths

Tailored specifically to route of administration; broad database search; distinguishes smoking, vaping, oral use, and dabbing.

Limitations and potential bias

Highly heterogeneous evidence; includes reviews and case reports alongside primary studies; no meta-analysis; the authors themselves describe route-specific conclusions as preliminary.

Muheriwa-Matemba SR, Baral A, Abdshah A, Diggs BA, Gerber Collazos KS, Morris KB, Messiah SE, Vidot DC. 2024. Cardiovascular and Respiratory Effects of Cannabis Use by Route of Administration: A Systematic Review. Substance use & misuse. DOI: 10.1080/10826084.2024.2341317 · PMID 38644600

Ghasemiesfe M et al. (2018)

Study

Systematic review and meta-analysis

Sample

22 studies (10 prospective cohorts, 12 cross-sectional studies).

Comparison and measurement

PubMed, Embase, PsycINFO, MEDLINE, Cochrane 1973–30.04.2018; PROSPERO; 4 reviewers for extraction/RoB, 3 for strength of evidence; pooling only of similar studies with sufficiently low risk of bias.

Randomisation and blinding

Predominantly non-randomised observational studies.

Result

22 studies in total. Pooled prospective symptom data from two studies: cough RR 2.04 (95% CI 1.02–4.06), sputum RR 3.84 (1.62–9.07). The authors rated the strength of evidence for respiratory symptoms as low; for obstruction and lung function as insufficient.

Strengths

Very rigorous methodology; PROSPERO registration; multiple reviewers; risk-of-bias and evidence-quality assessment; nuanced conclusions.

Limitations and potential bias

Primary studies mostly observational; exposure measurement and tobacco confounding; limited data at very high lifetime exposure.

Ghasemiesfe M, Ravi D, Vali M, Korenstein D, Arjomandi M, Frank J, Austin PC, Keyhani S. 2018. Marijuana Use, Respiratory Symptoms, and Pulmonary Function: A Systematic Review and Meta-analysis. Annals of internal medicine. DOI: 10.7326/M18-0522 · PMID 29971337 · PMC6231497

Lanz C et al. (2016)

Study

In-vitro device and aerosol validation

Sample

No human participants; 5 commercial dry-herb vaporizers, THC-dominant and CBD-dominant plant material.

Comparison and measurement

GC/MS for cannabinoid recovery in collected aerosol, HPLC for acidic cannabinoids and decarboxylation; Volcano Medic, Plenty, Arizer Solo, DaVinci, and a gas-powered device.

Randomisation and blinding

Not applicable.

Result

Electrically temperature-controlled devices decarboxylated THC/CBD very efficiently and delivered cannabinoids reproducibly; combustion was observed with the gas-powered device.

Strengths

Validated analytical methods; multiple devices; direct measurement of material transfer.

Limitations and potential bias

No human participants, no clinical endpoints, no comprehensive toxicological aerosol analysis; device generations are older.

Lanz C, Mattsson J, Soydaner U, Brenneisen R. 2016. Medicinal Cannabis: In Vitro Validation of Vaporizers for the Smoke-Free Inhalation of Cannabis. PloS one. DOI: 10.1371/journal.pone.0147286 · PMID 26784441 · PMC4718604

Hazekamp A et al. (2006)

Study

Device and dose evaluation study with analytical and clinical components

Sample

Primarily device and laboratory characterisation; human component for inhalation and exhalation balance, exact number of participants not reported in the abstract.

Comparison and measurement

Variation of temperature, sample, and balloon volume; inter- and intra-device variability; loaded versus delivered THC dose; clinical inhalation measurements.

Randomisation and blinding

No/not a classical RCT.

Result

On average, approximately 54% of the loaded THC dose reached the balloon; approximately 35% of the inhaled THC was exhaled again.

Strengths

Reproducibility and dose validation; important methodological basis for subsequent Volcano studies.

Limitations and potential bias

No long-term toxicology; outdated hardware and products; health-related conclusions are indirect.

Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R. 2006. Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. Journal of pharmaceutical sciences. DOI: 10.1002/jps.20574 · PMID 16637053

Gieringer D, St. Laurent J, Goodrich S (2004)

Study

Analytical laboratory study

Sample

No human subjects; cannabis smoke/vapour generated under controlled device conditions.

Comparison and measurement

Chemical analysis of vaporizer aerosol compared with smoke, focusing on THC transfer and pyrolytic by-products.

Randomisation and blinding

Not applicable.

Result

Vaporization delivered THC with markedly suppressed combustion and pyrolysis products compared with smoke.

Strengths

Direct chemical mechanism for harm reduction.

Limitations and potential bias

Dated; no clinical outcomes; journal and methodology less robust than modern toxicological studies; results are device- and product-dependent.

Gieringer D, St. Laurent J, Goodrich S. 2004. Cannabis Vaporizer Combines Efficient Delivery of THC with Effective Suppression of Pyrolytic Compounds. Journal of Cannabis Therapeutics. DOI: 10.1300/J175v04n01_02

Moir D et al. (2008)

Study

Analytical Machine-Smoking Study

Sample

No human subjects; standardised cannabis and tobacco cigarettes smoked under two machine-smoking conditions.

Comparison and measurement

Chemical characterisation of mainstream and sidestream smoke; known toxic and carcinogenic constituents.

Randomisation and blinding

Not applicable.

Result

Qualitatively similar classes of harmful constituents to tobacco smoke, but quantitative differences; notably substantially higher ammonia as well as higher HCN/NOx and certain aromatic amines under particular cannabis-smoke conditions.

Strengths

Direct standardised chemical comparison; objective analytical methodology.

Limitations and potential bias

Machine-generated smoke does not represent real-world exposure; values are per amount of material, not per typical day of use; must not be reinterpreted as ‘cannabis is more harmful than tobacco’.

Moir D, Rickert WS, Levasseur G, Larose Y, Maertens R, White P, Desjardins S. 2008. A comparison of mainstream and sidestream marijuana and tobacco cigarette smoke produced under two machine smoking conditions. Chemical research in toxicology. DOI: 10.1021/tx700275p · PMID 18062674

Van Dam NT, Earleywine M (2010)

Study

Single-arm pre/post intervention study

Sample

20 frequent cannabis users with at least two respiratory symptoms; 12 without intercurrent respiratory illness formed the primary analysis.

Comparison and measurement

One month switching to a vaporizer; nine subjective respiratory symptoms plus spirometry (FEV1, FVC) before and after the intervention.

Randomisation and blinding

No.

Result

In the 12 participants without respiratory infection, symptoms improved markedly; FVC improved significantly; FEV1 improved numerically, narrowly falling short of significance.

Strengths

Prospective intervention; objective spirometry in addition to symptom measures.

Limitations and potential bias

Very small; no control group; selection of the 12 participants may introduce bias; short duration; no blinding.

Van Dam NT, Earleywine M. 2010. Pulmonary function in cannabis users: Support for a clinical trial of the vaporizer. The International journal on drug policy. DOI: 10.1016/j.drugpo.2010.04.001 · PMID 20451365

Earleywine M, Barnwell SS (2007)

Study

Cross-sectional online survey

Sample

6.883 evaluable participants; only 152 (2.2%) primarily used a vaporizer.

Comparison and measurement

Self-reported consumption method, age, sex, quantity of cigarettes and cannabis, and six respiratory symptoms; logistic regression.

Randomisation and blinding

No.

Result

Primary vaporizer use was associated with fewer self-reported respiratory symptoms after statistical adjustment (approximately OR 0.40).

Strengths

Very large overall sample; adjustment for key confounders.

Limitations and potential bias

Cross-sectional; self-selection via cannabis-related mailing lists; self-report; only 152 primary vaporizer users; no causal inference possible.

Earleywine M, Barnwell SS. 2007. Decreased respiratory symptoms in cannabis users who vaporize. Harm reduction journal. DOI: 10.1186/1477-7517-4-11 · PMID 17437626 · PMC1853086

Sun R et al. (2026)

Study

National longitudinal observational study (PATH)

Sample

5.211 young adults (aged 18–24) with no prior respiratory or pulmonary disease, Wave 6→7.

Comparison and measurement

Baseline 2021, follow-up to 2023; multivariable logistic regression, adjusted for demographics, other substances, health factors, obesity and cannabis frequency.

Randomisation and blinding

No.

Result

Vaping-only was not significantly associated with new functionally relevant respiratory symptoms (AOR 0.93; very wide CI); smoking-only AOR 3.04; dual use AOR 4.36. After excluding tobacco users, only dual use remained significant.

Strengths

Large longitudinal, nationally representative sample; baseline group free of respiratory disease; confounder adjustment.

Limitations and potential bias

Only 2.1% vaping-only → low statistical power and very wide CI; product type (dry-herb vaporizer vs. oil/cartridge) insufficiently granular; self-report.

Sun R, Benowitz NL, Hammond D, Mendez D, Warner KE. 2026. Cannabis Vaping, Smoking, and Dual Use and the Onset of Respiratory Symptoms Among U.S. Young Adults. American journal of preventive medicine. DOI: 10.1016/j.amepre.2026.108421 · PMID 42142848

Frequently Asked Questions

What exactly is being compared?

“Joint” can refer to a pure cannabis cigarette or a tobacco–cannabis mixture. For scientific comparison, this is far from a trivial distinction. Tobacco adds an additional exposure; switching from a tobacco joint to a tobacco-free vaporizer therefore changes more than just the heating method. Anyone applying study findings must keep these differences in mind. Muheriwa-Matemba et al. (2024) Ghasemiesfe et al. (2018)

Why can the same quantity of flower produce different effects?

The mass loaded into a device is only the start of the chain of effects. The potency of the starting material, transfer into smoke or aerosol, deposition within the device, and individual uptake together determine the exposure. The amount actually inhaled is therefore not identical to the quantity of THC loaded. Device recovery and bioavailability must be considered separately. Lanz et al. (2016) Hazekamp et al. (2006)

What changes for the airways?

The lower CO exposure observed in direct comparisons and laboratory findings on combustion products point to a different exposure profile. Whether and to what extent this translates into fewer long-term illnesses is not answered by these experiments. The claim of ‘no tar and no CO’ is just as problematic without a precise measurement definition as a general figure for all harmful substances. Abrams et al. (2007) Gieringer et al. (2004) Moir et al. (2008)

References

1. Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL. 2007. Vaporization as a smokeless cannabis delivery system: a pilot study. Clinical pharmacology and therapeutics. DOI: 10.1038/sj.clpt.6100200 · PMID 17429350
2. Spindle TR, Cone EJ, Schlienz NJ, Mitchell JM, Bigelow GE, Flegel R, Hayes E, Vandrey R. 2018. Acute Effects of Smoked and Vaporized Cannabis in Healthy Adults Who Infrequently Use Cannabis: A Crossover Trial. JAMA network open. DOI: 10.1001/jamanetworkopen.2018.4841 · PMID 30646391 · PMC6324384
3. Muheriwa-Matemba SR, Baral A, Abdshah A, Diggs BA, Gerber Collazos KS, Morris KB, Messiah SE, Vidot DC. 2024. Cardiovascular and Respiratory Effects of Cannabis Use by Route of Administration: A Systematic Review. Substance use & misuse. DOI: 10.1080/10826084.2024.2341317 · PMID 38644600
4. Ghasemiesfe M, Ravi D, Vali M, Korenstein D, Arjomandi M, Frank J, Austin PC, Keyhani S. 2018. Marijuana Use, Respiratory Symptoms, and Pulmonary Function: A Systematic Review and Meta-analysis. Annals of internal medicine. DOI: 10.7326/M18-0522 · PMID 29971337 · PMC6231497
5. Lanz C, Mattsson J, Soydaner U, Brenneisen R. 2016. Medicinal Cannabis: In Vitro Validation of Vaporizers for the Smoke-Free Inhalation of Cannabis. PloS one. DOI: 10.1371/journal.pone.0147286 · PMID 26784441 · PMC4718604
6. Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R. 2006. Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. Journal of pharmaceutical sciences. DOI: 10.1002/jps.20574 · PMID 16637053
7. Gieringer D, St. Laurent J, Goodrich S. 2004. Cannabis Vaporizer Combines Efficient Delivery of THC with Effective Suppression of Pyrolytic Compounds. Journal of Cannabis Therapeutics. DOI: 10.1300/J175v04n01_02
8. Moir D, Rickert WS, Levasseur G, Larose Y, Maertens R, White P, Desjardins S. 2008. A comparison of mainstream and sidestream marijuana and tobacco cigarette smoke produced under two machine smoking conditions. Chemical research in toxicology. DOI: 10.1021/tx700275p · PMID 18062674
9. Van Dam NT, Earleywine M. 2010. Pulmonary function in cannabis users: Support for a clinical trial of the vaporizer. The International journal on drug policy. DOI: 10.1016/j.drugpo.2010.04.001 · PMID 20451365
10. Earleywine M, Barnwell SS. 2007. Decreased respiratory symptoms in cannabis users who vaporize. Harm reduction journal. DOI: 10.1186/1477-7517-4-11 · PMID 17437626 · PMC1853086
11. Sun R, Benowitz NL, Hammond D, Mendez D, Warner KE. 2026. Cannabis Vaping, Smoking, and Dual Use and the Onset of Respiratory Symptoms Among U.S. Young Adults. American journal of preventive medicine. DOI: 10.1016/j.amepre.2026.108421 · PMID 42142848

Editorial status: 10 September 2026. Evidence-based overview based on a selected library of 34 publications; no independent systematic literature search and no medical review. Bibliographic details and available abstracts were verified; the key works by Spindle (2018) and Lanz (2016) were additionally checked in open full text. Technical selection and maintenance guidance should be distinguished from health evidence. New data may change this assessment.